Agios Pharmaceuticals Stock Slumps After Novo Nordisk's Superior SCD Drug Results
Agios Pharmaceuticals (AGIO) stock fell 26.8% following Novo Nordisk's (NVO) announcement that its drug etavopivat outperformed Agios' mitapivat in Phase 3 trials for sickle cell disease. Novo's drug met both primary endpoints, while Agios' drug failed one. Agios has a potential 2026 pipeline catalyst with tebapivat.
Topics: Clinical Trial Results Drug Competition Regulatory Risk Sickle Cell Disease Stock Price Movement